Staging and assessment of hepatobiliary malignancies

Published on 11/04/2015 by admin

Filed under Surgery

Last modified 11/04/2015

Print this page

This article have been viewed 2333 times

Staging and assessment of hepatobiliary malignancies

Steve M.M. de Castro, Otto M. van Delden, Dirk J. Gouma and Olivier R.C. Busch

Introduction

Selection in patients with hepato-pancreato-biliary (HPB) malignancy is of the utmost importance. Patient selection should ideally identify those who might benefit from surgery and those who will not. Palliation for the majority of patients with unresectable or incurable disease utilises minimally invasive techniques (i.e. endoscopic or percutaneous biliary stenting, radiochemotherapy). Technological advances have changed the approach to evaluate patients with suspected HPB disease. Modern state-of-the-art imaging now allows physicians to focus on two key questions in patients with suspected HPB tumours. Is there really a malignant tumour present? If so, can it be removed with an R0 resection?

This chapter focuses on the diagnostic work-up of patients with the most common HPB malignancies and discusses the staging and assessment of resectability.

Colorectal liver metastases

Imaging of colorectal liver metastases (CRLMs) is important in patient assessment in several aspects. Firstly, to detect as many liver metastases as possible with their exact location within the liver, in order to maximise the chance of achieving complete clearance of disease at surgery. Secondly, to characterise any benign liver lesions that may be present, so as to avoid unnecessary surgical procedures.

Ultrasound has a diagnostic sensitivity of 36–61% for detecting lesions measuring 1–2 cm, even when performed by experienced radiologists.¹ It is very useful in guiding fine-needle aspiration (FNA) to confirm unresectability by cytopathology. However, FNA has a risk of seeding metastases in up to10% of patients and a risk of a false-negative result, which does not justify its use in candidates for potentially curative therapy.²

A meta-analysis of the performance of ultrasound for CRLMs found a pooled sensitivity of 63% (95% confidence interval (CI) 56–70%; five studies) with a specificity of 97.6% (95% CI 95.6–99.5%; four studies).³

Ultrasound can be very useful as a problem-solving tool when computed tomography (CT) or magnetic resonance imaging (MRI) is uncertain. A targeted ultrasound of a suspicious lesion can often discriminate between a benign and malignant lesion.

MRI, though not as widely available as CT, is the preferred first-line modality for evaluating CRLM; it provides anatomical detail and has a high detection rate, even for lesions less than 10 mm in diameter. FDG-PET is valuable in the evaluation of extrahepatic disease.

Computed tomography and magnetic resonance imaging

Nowadays, CT is the most commonly used imaging modality for staging and follow-up of these patients. Current multidetector scanners allow for multiplanar reformatting with the same resolution as the original axial images. This may improve detection and characterisation of small lesions.³ Multiplanar reformatting also enables the demonstration of hepatic arterial, venous and portal anatomy, which can be useful in preoperative planning.⁴ CT allows for accurate volumetric assessment of tumour size, liver volume to be resected and future liver remnant volume.⁵

A multiphase contrast-enhanced CT should be performed to stage liver metastases. The study should include an unenhanced, arterial, portovenous and delayed phase. CRLMs may show an enhancing rim on arterial phase imaging and are hypodense on portovenous phase imaging (Fig. 3.1). A slice thickness of 2–4 mm is recommended for axial viewing.

Figure 3.1 Patient with liver metastases in segment 7 and small adjacent satellite lesion on CT.

A meta-analysis on the performance of CT found a pooled sensitivity of 74.8% (95% CI 71.2–78.3%; 12 studies) and specificity of 95.6% (95% CI 93.4–97.8%; seven studies).³

The standard MRI protocol includes T2-weighted, unenhanced T1-weighted and dynamic contrast-enhanced T1-weighted sequences. T2-weighted images are used for the detection and characterisation of lesions (haemangioma, cyst).⁶^,⁷

A meta-analysis on the performance of MRI found a pooled sensitivity of 81.1% (95% CI 76.0–86.1%; five studies) and specificity of 97.2% (95% CI 94.5–99.9%; two studies).³ On per lesion analysis, MRI appeared to be the modality showing higher sensitivities across individual studies compared to CT. Pooled data showed comparable results, with MRI having a combined sensitivity of 88% and accuracy of 87% compared to CT with sensitivity of 74% and accuracy of 78%. Therefore, most centres choose the imaging technique of their preference.

Subgroup analyses of these studies showed that MRI has better sensitivity at picking up the smaller lesions < 1 cm compared to CT and also positron emission tomography (PET)-CT.⁸ The majority of lesions missed by CT and PET-CT were micrometastases of < 1 cm. This meta-analysis concludes that MRI is preferred as a first-line modality for evaluating the liver. It has high overall sensitivity and specificity estimates and can accurately depict lesions smaller than 10 mm. Secondly, it provides excellent anatomical details.

Positron emission tomography

Fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET is a well-established non-invasive functional scanning method, where a labelled glucose molecule is injected intravenously. The principle of FDG-PET is that malignant cells have a higher glucose uptake than regular cells. The scanner performs a rapid non-invasive interrogation of glycolytic activity throughout the whole body in a single imaging session. Besides being used for the detection of primary malignant tumours, it also can be used to detect regional and distant metastases, to differentiate benign from malignant disease or recurrent cancer from treatment-related scarring, and to evaluate response to therapy.

With the PET-CT combination it is possible to produce fusion images with high-resolution anatomical localisation of CT together with the functional data of FDG-PET. This combination of scanning characteristics is becoming more widely available (Fig. 3.2).

Figure 3.2 PET-CT of same patient with CRLMs showing two distinct lesions.

Kinkel et al.⁹ performed a meta-analysis and concluded that, at equivalent specificity, PET-CT is more sensitive than ultrasound (US), CT and MRI for the detection of hepatic metastases from gastrointestinal cancers.

Bipat et al.¹⁰ performed a meta-analysis and concluded that PET-CT is the most sensitive diagnostic tool for the detection of hepatic metastases from colorectal cancer on a per-patient basis, but not on a per-lesion basis. The authors suggest that in patients requiring further work-up, FDG-PET can be used as a second-line modality because both sensitivity and specificity were high and FDG-PET plays a role in detecting extrahepatic disease.

Mainenti et al.¹¹ found that PET-CT showed a trend to perform better than the other modalities. The pooled estimates of a meta-analysis for PET-CT was 93.8% (95% CI 90.0–97.7; six studies) and specificity per patient was 98.7% (95% CI 97.2–100%; six studies).³

Diagnostic laparoscopy and laparoscopic ultrasound

Diagnostic laparoscopy is used to detect small peritoneal metastases or subcapsular liver metastases, which can be missed on non-invasive imaging. The addition of laparoscopic ultrasound (LUS) may increase the detection of small intrahepatic metastases. There are not many prospective studies on these specific patients and most retrospective series also include patients with other liver tumours.

Recent prospective studies have reported a limited benefit and found that an unnecessary laparotomy can be prevented in 10–13% of patients with CRLMs,¹²^,¹³ which is considerably lower than in earlier reports, where the figure varies from 12% to 33%.^14–16

One reason for the lower yield might be that the indications for resection for metastases have changed towards a more aggressive approach for multiple lesions and bilobar disease. Furthermore, the use of local ablative techniques such as radiofrequency ablation (RFA) in combination with resection and downsizing with chemotherapy has extended the possibilities for surgical treatment. Currently the only absolute restrictions for curative resection include unresectable extrahepatic dissemination and limited function of the (future) liver remnant. The varying definition of unresectablility has a linear correlation with the yield of laparoscopy. In addition, improved cross-sectional imaging techniques in recent years have also decreased the yield of diagnostic laparoscopy.

Several centres favour the selective use of laparoscopy. Jarnagin et al.¹³ have described a clinical risk score (CRS) that predicted survival after hepatic resection and was also suitable in identifying high-risk patients most likely to benefit from laparoscopy. In a study of 103 patients, occult unresectable disease was found in 12% of patients with a low score versus 42% of patients with a high score.¹³^,¹⁷ Similarly, in a series of 200 patients, a detection rate of only 6% was reported in patients with the lowest CRS, whereas this was 75% for the highest CRS scores.¹⁴ Another study demonstrated a yield of 50% in a selected group of patients, while in the group of 49 patients selected for direct surgical exploration, 46 patients (94%) were eventually resected.¹⁵

Staging and assesment of resectability

Factors that have favourable impact on survival are tumour-free resection margin, low level of carcinoembryonic antigen (CEA), single metastatic deposit and node-negative disease.¹⁸

The significance of resection margins of less than 10 mm is not clear.¹⁹ The results of this meta-analysis demonstrate that a negative margin of 1 cm or more confers a survival advantage when compared with subcentimeter negative margins. The management of synchronous liver metastases and extrahepatic abnormalities (particularly the hilar lymph nodes) is also unclear. There is a huge variation in techniques for resection (anatomical vs. non-anatomical, vena cava reconstruction, etc.). Although promising, clear results on the effectiveness of combination treatments with (neo)adjuvant chemotherapy are still lacking.

The optimal selection of patients for hepatic resection is evolving, and the criteria for resectability differ among individual liver surgeons.

A consensus statement in 2005 defined resectability as absence of non-treatable extrahepatic disease, fitness for surgery, ability to leave 30% of residual liver parenchyma in healthy livers or disease in no more than six segments.²⁰

Modern multidisciplinary consensus defines resectable CRLM simply as tumours that can be resected completely, leaving an adequate liver remnant.²¹ Before surgical exploration, most surgeons would require that there was no radiographic evidence of involvement of the hepatic artery, major bile ducts, main portal vein, or coeliac/para-aortic lymph nodes, and an adequate predicted functional hepatic remnant.²²

Some centres with extensive expertise do perform resections directly adjacent to major vascular structures with margins less than 10 mm; however, a margin of 10 mm is still recommended.¹⁹

In the presence of a limited number of lesions in the lung, liver resection is generally performed first. After radical resection of liver metastases, resection of the lung can follow. There is no reason to refrain from liver resection in a patient with advanced age who has good general (cardiopulmonary) fitness. Risk scoring systems (such as the clinical risk score ²³ and others^24–26) to predict which patients with CRLMs are most likely to benefit from resection are of uncertain clinical utility, particularly since most patients undergo different neoadjuvant chemotherapy regimens. Some studies have shown that the risk scoring system needs refinement²⁷^,²⁸ and that the outcome in patients treated by neoadjuvant chemotherapy was not predicted by the traditional clinical scoring system, but rather by response to chemotherapy as evaluated by CT and PET-CT.²⁹

Resection of synchronous metastases should be considered in selected patients. Other strategies such as RFA, portal vein embolisation and isolated liver perfusion fall beyond the scope of this chapter.

Hepatocellular carcinoma

The diagnosis of hepatocellular carcinoma (HCC) is challenging as it has a variable imaging appearance and because lesion detection is difficult against the inhomogeneous background of liver cirrhosis with dysplastic and regenerating nodules mimicking HCC.

Transabdominal ultrasound

Transabdominal ultrasound is recommended by the European Associasion for the Study of the Liver (EASL), the American Association for the Study of Liver Disease (AASLC) and the Asian Pacific Association for the Study of Liver Disease (APASL) as a surveillance tool for patients at high risk of developing HCC. Meta-regression analysis has demonstrated a significantly higher sensitivity for early HCC with US every 6 months than with annual surveillance.³⁰

Computed tomography and magnetic resonance imaging

Multiphase contrast-enhanced CT or MRI should be performed when evaluating HCC. The hallmark of HCC on CT and MRI is strong arterial enhancement (Fig. 3.3) and washout of contrast agent in the delayed phase (Fig. 3.4).³¹ This feature in particular enables differentiation from intrahepatic cholangiocarcinoma, which shows delayed enhancement.³²

Figure 3.3 CT image of patient with HCC in the liver showing arterial enhancement of the lesion.

Figure 3.4 CT image of same patient with HCC in the liver showing venous washout of the lesion with enhancing rim.

HCC arising in a non-cirrhotic liver is often large, due to its long asymptomatic course and late presentation.³³ This contrasts with the multifocal tumours more commonly found in patients with chronic liver disease, who are often in surveillance programmes. Large HCCs may demonstrate a number of characteristic appearances on CT, which make differentiation from other causes of focal liver masses relatively straightforward. These features include mosaic appearance, with fibrous septa separating areas of variable attenuation which represent internal regions of haemorrhage, necrosis, fatty degeneration and fibrosis. The fibrous capsule has a low attenuation on unenhanced images and enhances on the portal venous phase.

A number of benign lesions, including haemangiomas, focal confluent fibrosis, peliosis, benign regenerative nodules and transient hepatic attenuation difference, can mimic small HCC lesions on CT.³⁴

On MRI, HCCs can have a variable appearance on unenhanced T1-weighted images and typically show an increased signal on T2-weighted images.³⁵ Following gadolinium administration, HCC demonstrates characteristic early enhancement on arterial phase imaging³⁶ and washout on delayed images, resulting in a hypo-intense lesion compared to the surrounding parenchyma.³⁷

Diagnostic laparoscopy and laparoscopic ultrasound

Laparoscopic evaluation can avoid exploratory laparotomy in 45–63% of patients with unresectable disease.³⁸^,³⁹ The procedure has been shown to be accurate in assessing the presence of advanced intrahepatic disease and the quality of the liver remnant, but it was less sensitive in determining the extent of local invasion, especially in large (> 10 cm) tumours. Another study clearly reported the value of LUS in detecting small HCCs; 134 new nodules were visualised with this technique in 64 of 186 (34%) patients in whom 28 nodules (in 23 patients) were histologically diagnosed as HCC.⁴⁰ Of these 23 patients, 18 were diagnosed as having a solitary HCC before laparoscopy. Similarly, new lesions of histologically proven HCC were found in 22% of patients.⁴¹ Even when preoperative staging includes a CT, LUS was superior in detecting additional tumours.⁴² Ultrasound confirmed all 201 tumours seen on CT and detected 21 additional tumours (9.5%) in 11 patients (20%).

Staging and assesment of resectability

Tumour staging to select a treatment regimen is complicated by the fact that many of the staging systems (including the TNM staging system of the American Joint Committee on Cancer (AJCC) – see Table 3.1) are based on surgical findings, while surgery is applicable to only about 5% of these patients. Others recommend the Barcelona Clinic Liver Cancer (BCLC) staging system.⁴³ The Barcelona algorithm does not address the value of resection for some subgroups of patients with HCC who may potentially benefit from this approach, including some patients defined as being ‘early stage’ (with a single tumour size > 2 cm or multiple nodules) and ‘intermediate stage’ (patients who have multinodular tumours but a good performance status). The Milano/Mazzaferro criteria for liver transplantation for HCC (i.e. solitary tumour ≤ 5 cm or up to three tumours all ≤ 3 cm) are widely accepted.⁴⁴ However, according to the Barcelona algorithm, only selected patients with three nodules ≤ 3 cm (those without ‘associated diseases’) should also undergo liver transplantation.⁴³ The American Hepato-Pancreato-Biliary Association (AHPBA)/American Joint Commission on Cancer (AJCC) Consensus Conference on HCC in 2002 concluded that no single staging system could be used to accurately stage patients across the spectrum of HCCs.⁴⁴^,⁴⁵

Table 3.1

TNM staging for hepatocellular cancer

Note: cTNM is the clinical classification, pTNM is the pathological classification.

^*The fibrosis score as defined by Ishak is recommended because of its prognostic value in overall survival. This scoring system uses a 0–6 scale.

^†Data from AJCC sixth edition.

Modified from the AJCC Cancer Staging Manual, seventh edition (2010), published by Springer, New York.

The ideal patient for resection has a solitary HCC confined to the liver that shows no radiographic evidence of invasion of the hepatic vasculature, no evidence of portal hypertension and well-preserved hepatic function. According to the current TNM/UICC staging system for HCC (Table 3.1), most consider stage IIIB, IIIC, IVA or IVB disease to be incurable by resection. However, hepatic resection for stage IIIB, IIIC and IVA disease may be considered in some centres of excellence as clinical benefits, and long-term survival can be achieved in a selected minority of patients.

Assessment of hepatic reserve is paramount to selection for resection. Postoperative mortality is twice as high in cirrhotic as in non-cirrhotic patients unless proper patient selection is applied. For patients with cirrhosis, surgical resection can safely be performed in those with Child–Pugh class A disease. These patients should undergo assessment of liver volumetry and remaining function. Other indications for therapies such as liver transplantation, RFA, ablation and arterial chemoembolisation are discussed elsewhere.

Interval US at 6 months is recommended as a screening tool, while CT and MRI are most useful to confirm the diagnosis. Laparoscopic staging is useful in these patients since these tumours tend to be at high risk of being unresectable. The value of laparoscopy is further increased due to its capacity to aid guided biopsies of the future liver remnant in patients with cirrhosis.

Pancreatic and periampullary carcinoma

Most pancreatic tumours are located in the head of the pancreas (60–65%), while 20% are present in the body and 10% in the tail region. Unfortunately only a minority (5–20%) of pancreatic tumours are resectable. Tumours in the pancreatic head often present earlier due to compression of the adjacent common bile duct causing obstructive jaundice. Therefore these tumours are often smaller at time of presentation and more often resectable. These smaller tumours (< 2 cm) without liver metastases have better 5-year survival.⁴⁶ Hence, by accurately detecting and staging smaller tumours, imaging has the potential to influence survival.

The goal of imaging for pancreatic tumours is twofold. The first is to accurately identify tumours with local invasion or distant metastasis to tailor the treatment strategy, and the second is to accurately image the anatomical variations prior to resection.

Transabdominal ultrasound

This is usually the first screening examination of the abdomen in patients with obstructive jaundice. It is a useful diagnostic modality with a reasonable sensitivity (> 90%) for detecting bile duct obstruction, determining the level of the obstruction (e.g. intrahepatic, proximal or distal) and identifying the presence of gallstone disease.⁴⁷ Transabdominal ultrasound is cost-effective, widely available but highly operator dependent and often limited by the inability to adequately visualise the pancreas due to bowel gas interference. The goal of ultrasound is therefore to primarily establish a differential diagnosis among the various causes of obstructive jaundice and in identifying liver metastases. Ultrasound is highly sensitive in detecting gallbladder stones (> 90%),⁴⁸ but this sensitivity drops to 50–75% for the detection of bile duct stones.⁴⁹ On ultrasound, a pancreatic tumour appears as a hypoechoic (poorly reflective) mass. A tell-tale sign suggestive of malignant obstruction is the combined presence of a dilated common bile duct and pancreatic duct (double duct sign).

Ultrasound is able to detect most pancreatic masses of at least 3 cm, as was shown in a meta-analysis of 14 studies.⁵⁰ Pancreatic tumours (irrespective of size) yielded a sensitivity of 76% and a specificity of 75%.

However, these results are from studies performed in centres with significant experience in the diagnostic work-up of patients with pancreatic cancer. Doppler ultrasound can show vascular involvement of portal and mesenteric veins.

Additionally, transabdominal ultrasound has a high sensitivity for detecting liver metastases and ascites, and an FNA can be performed. Sensitivity for liver lesions depends on the size of the lesion and is > 90% for lesions larger than 2 cm, 60% for lesions of 1–2 cm and 20% for lesions < 1 cm in diameter.¹

Computed tomography and magnetic resonance imaging

CT is the most widely used imaging modality for pancreatic disease and staging pancreatic tumours. Modern multidetector CT enables evaluation of the vascular and ductal structures, and mapping of the anatomy and anatomical variations. The most important goal of CT imaging, besides the detection of tumours, is the assessment of resectability.

Tumour conspicuity depends heavily on CT scanning phases. Currently, a combination of pancreatic and portal phase CT is the optimal technique for pancreatic lesions. The best oral contrast is water. The optimal CT section thickness is 2 mm.

The arterial phase optimally demonstrates the arterial vessels (superior mesenteric artery, coeliac artery and hepatic artery) and their relation to the pancreatic tumour (Fig. 3.5). The portal venous phase demonstrates the portal and superior mesenteric veins and the junction (the confluence) at the pancreatic neck (Fig. 3.6). The parenchymal phase is between these two phases and demonstrates pancreatic adenocarinoma as a hypovascular tumour compared to the rest of the parenchyma.